UBS Group’s Arcellx ACLX Stock Holding History

UBS Group’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.41M	Buy	+12,300	New	+$1.09M	﹤0.01%	5272

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UBS Group's ACLX Position: Q1 2026 in Review

UBS Group reduced its Arcellx (ACLX) stake by 39% in Q1 2026, selling an estimated $10.8M and leaving 194,709 shares worth $22.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2473.

UBS Group first reported a position in ACLX in Q1 2022 and has held it in 17 quarters since. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

UBS Group held 194,709 shares of Arcellx worth $22.4M as of Q1 2026.
UBS Group sold 121,903 Arcellx shares in Q1 2026, an estimated $10.8M.
Arcellx made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2473 holding.
UBS Group first reported a position in Arcellx in Q1 2022 and has held it in 17 quarters since.
239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.